Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from PFE

Is Pfizer Stock Underperforming the Dow?

Although Pfizer underperformed the Dow Jones this year, analysts are moderately bullish on the stock’s prospects.

Barchart

3 Stocks Benefiting From the Aging Population

As the aging population drives significant opportunities for companies involved in pharmaceuticals, medical devices, and health care services, let’s not miss out on investing in quality stocks like Thermo Fisher Scientific (TMO), Medtronic (MDT), and Korn Ferry (KFY), which are poised to meet the needs of an aging demographic. Learn…

StockNews.com

3 High-Yield S&P 500 Stocks to Buy and Hold

Three high-yield S&P 500 stocks, Devon Energy, Verizon Communications, and Pfizer Inc., are poised to provide a balanced mix of income and growth, making them attractive options for long-term investors.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Healthcare Stocks Positioned for Major Gains in 2024

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

StockNews.com

3 Must-Buy Healthcare Stocks for Defensive Investing

The healthcare sector is set for significant growth due to advancements in pharma technology, increasing demand for personalized medicines, and resilience even in economic downturns. Therefore, investors might consider buying quality pharmaceutical stocks like Pfizer (PFE), Johnson & Johnson (JNJ), and AbbVie (ABBV) for defensive investing. Read on.

StockNews.com

2 Dividend Stocks to Buy in August If the Market Crash Scares You

Volatility is back on Wall Street, which is bound to scare some investors. Meanwhile, Pfizer and Starbucks are two high dividend names with limited downside which conservative investors can consider now.

Barchart

Is Wall Street Bullish or Bearish on Pfizer Stock?

Pfizer has underperformed relative to the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s outlook.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Pfizer Stock Slips After Beat-And-Raise Quarter: What to Know

Pfizer reported a notable year-over-year decline in Q2 earnings, but the results still beat expectations. Here's what investors should know.

Kiplinger

1 High-Yield Dividend Stock to Buy and Hold

Pfizer's stock shows signs of a potential rebound, buoyed by recent pipeline successes in hemophilia and obesity treatments, an attractive 5% dividend yield, and a rock-bottom valuation. This makes it an appealing dividend stock for value and income investors as the drug giant prepares to report earnings.

Barchart

Here's What to Expect From Pfizer’s Next Earnings Report

As Pfizer gears up to release its second-quarter earnings this month, analysts project a double-digit bottom-line dip.

Barchart

1 Big Pharma Dividend Stock to Snag While It's Still Cheap

Pfizer's stock presents a compelling investment opportunity, trading at an attractive valuation with a high dividend yield, as the company makes promising progress on its oral obesity drug, danuglipron, in a market dominated by injectable treatments.

Barchart

Patriots for Europe? Viktor Orbán’s new EU group is another hollow victory for the far right

Marine Le Pen’s RN and Hungary’s Fidesz have joined forces. But Europe’s far right is fractured and Orbán isolated, says political scientist Cas Mudde

The Guardian - UK

3 Value Stocks to Buy and Hold for Passive Income

Amid market volatility, three value stocks - American International Group (AIG), Pfizer (PFE), and Schlumberger (SLB) - emerge as potential long-term investments for passive income, offering attractive valuations, solid dividends, and growth prospects for investors.

Barchart

3 Ultra High-Yield Dividend Stocks to Pounce On at Every Dip

These dividend stocks have consistently paid dividends with yields over 6%.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Pfizer Stock Underperforming the Nasdaq?

Pfizer has recently lagged the Nasdaq Composite, but analysts are optimistic about the stock’s prospects.

Barchart

Should You Buy This S&P 500 Stock with a Dividend Yield of Nearly 6%?

With a dividend yield of nearly 6%, pharma giant Pfizer is among the highest-yielding S&P 500 stocks. While the stock's price action has been disappointing like most other high-dividend stocks, it looks worth a bet given the tepid valuations.

The Independent UK

A journey of global expansion and resilience in freight forwarding

As we celebrate the launch of the E2E International 100, we spoke to Adam Collins, Managing Director of PFE Express, a freight forwarding and logistics company, to gain further insights into his international business journey, discovering some of the challenges faced in the industry, and what strategies were implemented to help…

StockNews.com

Dividend Stability and Growth in Pharma: Pfizer (PFE) vs. Bristol-Myers Squibb (BMY)

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 Covered Call Ideas on Pfizer Stock

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

StockNews.com

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Barchart

5 Underperforming Stocks That Look Ready to Rebound, According to Goldman

Analysts at Goldman Sachs think these 5 underperforming stocks could be poised to outperform, thanks to a healthy valuation discount and expected EPS growth.

Barchart

2 Defensive Stocks to Buy Now as 'Higher For Longer' Woes Rattle Markets

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

Barchart

Down 32% in a Year, Should Investors Buy the Dip in Pfizer Stock?

Down more than 30% in a year, pharmaceutical company Pfizer trades near its 52-week lows. Is this the right time to buy in the dip?

Barchart

2 Cheap Dividend Stocks to Buy This March and Hold for the Long Term

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

StockNews.com

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

1 … 4 5 6 7

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.